Can a Patient's own immune cells beat advanced kidney cancer?

NCT ID NCT07770802

First seen Aug 18, 2026 · Last updated Aug 18, 2026

Summary

This early-stage trial is testing an experimental therapy called HS-IT101 for people with advanced clear cell renal cell carcinoma, a type of kidney cancer. The treatment involves collecting immune cells from the patient's tumor, multiplying them in the lab, and infusing them back after a short course of chemotherapy to make room for them. The goal is to see if this personalized cell therapy is safe and can shrink or control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HS-IT101, a personalized cell therapy made from a patient's own tumor-infiltrating lymphocytes (TILs), given after a short course of chemotherapy (cyclophosphamide and fludarabine) and followed by interleukin-2 (IL-2) injections.
What this could lead to
If successful, this could lead to a new treatment option that harnesses the immune system to fight advanced kidney cancer, potentially offering long-term remission.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply broadly. The treatment involves intensive chemotherapy and IL-2, which can cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.